Lanthanum carbonate: A review of its use in lowering serum phosphate in patients with end-stage renal disease

Drugs

Volumn 69, Issue 16, 2009, Pages 2329-2349

  Curran, Monique P ^a   Robinson, Dean M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; MAGNESIUM SALT; PHOSPHATE; PLACEBO; SEVELAMER;

ABDOMINAL PAIN; ADULT; ANEMIA; BLOOD VESSEL CALCIFICATION; BONE TOXICITY; BRONCHITIS; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY FAILURE; LONG TERM CARE; MAGNESIUM BLOOD LEVEL; NAUSEA; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; REVIEW; RHINITIS; UPPER GASTROINTESTINAL TRACT; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANIMALS; CALCIUM CARBONATE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHATES; POLYAMINES; RENAL DIALYSIS; TIME FACTORS;

EID: 70350521062     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202610-000000000-00000     Document Type: Review

References (73)

1. Burke SK. Phosphate is a uremic toxin. J Ren Nut 2008 Jan; 18 (1): 27-32
2. Albaaj F, Hutchison A. Hyperphosphataemia in renal fail-ure: causes, consequences and current management. Drugs 2003; 63 (6): 577-596
3. Block GA, Hulbert-Shearon TE, Levin NW, et al. Associa-tion of serum phosphorus and calcium · phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 Apr; 31 (4): 607-617
4. Block GA, Klassen PS, Lazarus JM, et al. Mineral meta-bolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 Aug; 15 (4): 2208-2218
5. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008 Sep; 52 (3): 519-530
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 Oct; 42 (4 Suppl. 3): S1-201
7. Ashfaq A, Gitman M, Singhal PC, et al. Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease. Expert Opin Pharmacother 2006; 7 (14): 1897-1905
8. Shire US Inc. Fosrenol® (lanthanum carbonate): US prescribing information [online]. Available from URL: http://www.fosre nol.com/PDFs/ PrescribingInfo.pdf [Accessed 2009 May 10]
9. Shire Pharmaceuticals Limited. Fosrenol® 250mg, 500mg, 750 mg and 1000 mg chewable tablets: summary of product characteristics [online]. Available from URL: http:// emc. medicines.org. uk/document.aspx?documentid=19617 [Accessed 2009 May 1]
10. Swainston Harrison T, Scott LJ. Lanthanum carbonate. Drugs 2004; 64 (9): 985-996
11. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007 Oct; 96 (10): 2818-2827
12. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 2007 Dec; 23 (12): 3167-3175
13. Sprague SM, Abboud H, QiuP, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009 Jan; 4 (1): 175-185
14. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003 Jun; 63 Suppl. 85: S73-8
15. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006 Aug; 21 (8): 2217-2224
16. Freemont AJ, Hoyland JA, Denton J, on behalf of the Lanthanum Carbonate SPD 405-303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005 Dec; 64 (6): 428-437
17. Malluche HH, Siami GA, Swanepoel C, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008 Oct; 70 (4): 284-295
18. Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008; 110 (1): c15-23
19. Altmann P, Barnett ME, Finn WF, et al. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71 (3): 252-259
20. Damment SJP, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmaco-kinet 2008; 47 (9): 553-563
21. Pennick M, Dennis K, Damment SJ. Absolute bioavail-ability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006 Jul; 46 (7): 738-746
22. Finn WF, on behalf of the SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006 Mar; 65 (3): 191-202
23. Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol 2009 Mar; 71 (3): 286-295
24. Damment SJ, Cox AG, Secker R. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? Toxicol Lett 2009 Aug 10; 188 (3): 223-229
25. Bronner F, Slepchenko BM, Pennick M, et al. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008; 47 (8): 543-552
26. How PP, Fischer JH, Arruda JA, et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2007 Nov; 2(6): 1235-1240
27. Dammet S, Pennick M, Dennis K. A new 1000-mg formula-tion of lanthanum carbonate effectively reduces urinary phosphorus excretion in healthy volunteers [abstract no. F-PO982]. J Am Soc Nephrol 2005; 16: 550A
28. Finn WF, Joy MS, Hladik G. Efficacy and safety of lan-thanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004 Sep; 62 (3): 193-201
29. Shigematsu T, and the Lanthanum Carbonate Research Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008 Feb; 12 (1): 55-61
30. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005 Apr; 20 (4): 775-782
31. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol®) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005 Jun; 63 (6): 461-470
32. Joy MS, Finn WF, on behalf of the LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003 Jul; 42 (1): 96-107
33. Shigematsu T, and the Lanthanum Carbonate Group. Multi-center prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 2008 Nov; 70 (5): 404-410
34. Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbo-nate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009 Oct; 72 (4): 252-258
35. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, toler-ability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100 (1): c8-19
36. Finn WF, Joy MS, on behalf of the LAM-308 Study Group. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005 May; 21 (5): 657-664
37. Hutchison A J, Maes B, Vanwalleghem J, et al. Long-term ef-ficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006; 102 (2): c61-71
38. US Department of Health and Human Services-Food and Drug Administration. Statistical review and evaluation: clinical studies. Available from URL: http://www.fda.gov/ cder/foi/nda/2004/2 1-468-Fosrenol-StatrClinStudy.pdf [Accessed 2009 Apr 1]
39. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004 Jul; 19 (7): 1902-1906
40. Eknoyan G, Levin A, Levin NW, et al. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl. 3): 1-201
41. Hutchison AJ. Oral phosphate binders. Kidney Int 2009 May; 75 (9): 906-914
42. Shire Plc. Shire announces launch of FOSRENOL® in Japan: management of hyperphosphataemia in end-stage renal disease patients [media release]. Available from URL: http://www.medicalnewstoday.com/articles/142033.php [Accessed 2009 Mar 12]
43. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74 (2): 148-157
44. Ritz E. The clinical management of hyperphosphatemia. J Nephrol 2005; 18 (3): 221-228
45. Moe SM, Drueke TB, Block GA, et al. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 Aug; (113): S1-130
46. Kanbay M, Goldsmith D, Akcay Al, et al. Phosphate-the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 2009; 27: 220-230
47. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phos-phate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005 Feb; 16 (2): 520-528
48. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007 Oct; 22 (10): 2909-2916
49. Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17 (3 Suppl. 1): S1-27
50. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ 2008 Nov 18; 179(11): 1154-1162
51. Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association. Chronic kidney disease in adults: UK guidelines for identification, management and referral [online]. Available from URL: http://www.renal.org/CKDguide/full/UKCKDfull.pdf [Accessed 2009, Apr 22]
52. Elder G, Faull R, Branley P, et al. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology 2006; 11 Suppl.: S230-61
53. Mohammed IA, Hutchison AJ. Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. Ther Clin Risk Manag 2008 Oct; 4 (5): 887-893
54. Shinaberger CS, Greenland S, Kopple JD, et al. Is control-ling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008 Dec; 88 (6): 1511-1518
55. Pauly RP. Nocturnal home hemodialysis and short daily hemodialysis compared with kidney transplantation: emerging data in a new era. Adv Chronic Kidney Dis 2009 May; 16 (3): 169-172
56. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53 (5): 1399-1401
57. Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13 Suppl. 6: 148-151
58. Mohammed I, Hutchison A J. Oral phosphate binders for the management of serum phosphate levels in dialysis patients. J Ren Care 2009 Mar; 35 Suppl. 1: 65-70
59. Wills MR, Savory J. Aluminium poisoning: dialysis enceph-alopathy, osteomalacia and anaemia. Lancet 1983 Jul 2; II (8340): 29-34
60. Gonzalez-Revalderia J, Casares M, de Paula M, et al. Bio-chemical and haematological changes in low-level aluminium intoxication. Clin Chem Lab Med 2000 Mar; 38 (3): 221-225
61. Schaefer K, Umlauf E, von Herrath D. Reduced risk of hy-percalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992 May; 19 (5): 460-464
62. Goodman WG. Vascular calcification in chronic renal fail-ure. Lancet 2001 Oct; 358 (9288): 1115-1116
63. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Manage-ment of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002 May; 17 (5): 723-731
64. O'Donovan R, Baldwin D, Hammer M, et al. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1986 Apr; I (8486): 880-882
65. Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial 2007; 20 (4): 333-336
66. Goldsmith DR, Scott LJ, Cvetkovic RS, et al. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008; 68 (1): 85-104
67. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007 Dec; 68 (6): 386-391
68. Chertow G, Dillon M, Burke S, et al. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium: strategies for the control of hyper-phosphataemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999 Jan; 51 (1): 18-26
69. Karamanidou C, Clatworthy J, Weinman J, et al. A sys-tematic review of the prevalence and determinants of non-adherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008 Jan 31; 9 (2)
70. Tomasello S, Dhupar S, Sherman R. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dialysis Transplant 2004; 33: 236-242
71. US Renal Data System. Medication use among dialysis pa-tients in the Dialysis and Morbidity and Mortality Study. Am J Kidney Dis 1998; 32 (2 Suppl. 1): S60-8
72. Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008 Nov; 23 (11): 3677-3684
73. Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008 Sep; 3 (5): 1437-1445